Market news

- Expanded laboratory capabilities support deeper mechanism-of-action research for stenoparib - New proteomics and cell line capabilities will broaden Allarity’s research capabilities to enable external partnerships TARPON SPRINGS, Fla., September 28, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor— today announced that

TARPON SPRINGS, Fla., September 15, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—today announced that the Japan Patent Office (JPO) has granted a key patent covering Allarity’s proprietary stenoparib-specific Drug Response Predictor (DRP®) companion diagnostic. The newly granted patent, Japanese Patent No. 7917283, p

- Completed quarter with $26.9 million in cash and restricted cash - Key U.S. patent was awarded, protecting exclusivity of stenoparib when used with the stenoparib-specific DRP® companion diagnostic into 2042 - AACR 2026 data linked higher stenoparib DRP® scores with enhanced overall survival in advanced ovarian cancer, further supporting DRP®-guided patient selection - Obtained CLIA certification for its in-house laboratory, enabling full control of DRP® testing to accelerate and support U.S.

Here is how Allarity Therapeutics, Inc. (ALLR) and ANIXA BIOSCIENCES INC (ANIX) have performed compared to their sector so far this year.

Here is how Allarity Therapeutics, Inc. (ALLR) and Amgen (AMGN) have performed compared to their sector so far this year.